

CLAIMS:

1. A programmed death-ligand 1 (PD-L1) binding agent comprising an immunoglobulin heavy chain variable region polypeptide and an immunoglobulin light chain variable region polypeptide, wherein:
the immunoglobulin heavy chain variable region polypeptide comprises a complementarity determining region 1 (HCDR1) comprising any one of SEQ ID NOs: 1-23, 309, or 345, a complementarity determining region 2 (HCDR2) comprising any one of SEQ ID NOs: 24-57, 310-314, or 346-349, and a complementarity determining region 3 (HCDR3) comprising any one of SEQ ID NOs: 58-95, 315-318, or 350-354; or
the immunoglobulin light chain variable region polypeptide comprises a complementarity determining region 1 (LCDR1) comprising any one of SEQ ID NOs: 96-128, 319-323, 355, or 356, a complementarity determining region 2 (LCDR2) comprising any one of SEQ ID NOs: 129-151 or 357-359, and a complementarity determining region 3 (LCDR3) comprising any one of SEQ ID NOs: 152-176 or 360.
2. A PD-L1 binding agent comprising an immunoglobulin heavy chain variable region of any one of SEQ ID NOs: 223-264, 324-334, or 361-365 or at least the CDRs thereof; and an immunoglobulin light chain variable region of any one of SEQ ID NOs: 265-306, 335-344, or 366-370 or at least the CDRs thereof.
3. A PD-L1 binding agent comprising an immunoglobulin heavy chain variable region polypeptide with an amino acid sequence that is at least 90% identical to any one of SEQ ID NOs: 223-264, 324-334, or 361-365, and an immunoglobulin light chain variable region polypeptide with an amino acid sequence that is at least 90% identical to any one of SEQ ID NOs: 265-306, 335-344, or 366-370.
4. The PD-L1 binding agent of any one of claims 1-3, which comprises the heavy and light chain immunoglobulin polypeptides, or at least the CDRs thereof, of a PD-L1 binding agent of Table 1.
5. The PD-L1 binding agent of any one of claims 1-4, wherein the binding agent is an antibody, an antibody conjugate, or an antigen-binding fragment thereof.

6. The PD-L1 binding agent of claim 5, wherein the binding agent is an antibody fragment selected from F(ab')₂, Fab', Fab, Fv, scFv, dsFv, dAb, and a single chain binding polypeptide.
7. The PD-L1 binding agent of claim 5, wherein the binding agent is an antibody.
8. The PD-L1 binding agent of any of claims 1-7, further comprising an immunoglobulin Fc region.
9. The PD-L1 binding agent of claim 8, further comprising a transforming growth factor beta 1 (TGFβ1) receptor, or a fragment thereof that binds TGFβ1, attached to the Fc region.
10. The PD-L1 binding agent of any one of claims 7-9, wherein the antibody is an IgG, IgM, IgA, IgD or IgE antibody.
11. The PD-L1 binding agent of any one of claims 7-9, wherein the antibody is an IgG antibody.
12. The PD-L1 binding agent of any one of claims 7-11, wherein the antibody exhibits antibody dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), or complement dependent cytotoxicity (CDC).
13. The PD-L1 binding agent of any of claims 1-12, wherein the binding agent is part of a bispecific antibody, chimeric antigen receptor, chimeric T cell receptor, or bispecific T-cell engager.
14. The PD-L1 binding agent of any of claims 1-12, wherein the binding agent is an internalizing binding agent.
15. A nucleic acid encoding the heavy chain immunoglobulin polypeptide of the anti-PD-L1 binding agent of any one of claims 1-14.
16. A nucleic acid encoding the light chain immunoglobulin polypeptide of the anti-PD-L1 binding agent of any one of claims 1-14.

17. A nucleic acid encoding the heavy chain immunoglobulin polypeptide and the light chain immunoglobulin polypeptide of the PD-L1 binding agent of any one of claims 1-14.
18. A vector comprising the nucleic acid sequence of any one of claims 15-17.
19. An isolated cell comprising the nucleic acid of any one of claims 15-17, optionally in a vector.
20. A method of providing a PD-L1 binding agent of any of claims 1-14, the method comprising expressing in a cell *in vitro* one or more nucleic acids encoding the immunoglobulin heavy and light chain polypeptides thereof.
21. A composition comprising the PD-L1 binding agent of any one of claims 1-14 or nucleic acid of any one of claims 15-17, optionally in a vector, and a pharmaceutically acceptable carrier.
22. The PD-L1 binding agent of any one of claims 1-14 or conjugate comprising same, or the composition of claim 21, for use as a medicament for the treatment of a disease, disorder, or condition in a mammal that is responsive to PD-L1 inhibition or binding.
23. Use of the PD-L1 binding agent of any one of claims 1-14 or conjugate comprising same, or the composition of claim 21, in the manufacture of a medicament for the treatment of a disease, disorder, or condition in a mammal that is responsive to PD-L1 inhibition or binding.
24. The use of claim 23, wherein the disease, disorder, or condition is cancer.
25. The use of claim 23, wherein the disease, disorder, or condition is an autoimmune disorder.
26. The use of claim 23, wherein the disease, disorder, or condition is an infection.
27. The PD-L1 binding agent of any one of claims 1-14 or the composition of claim 19 for use as a medicament for the modulation of an immune response in a mammal.

28. Use of the PD-L1 binding agent of any one of claims 1-14 or the composition of claim 19 in the manufacture of a medicament for the modulation of an immune response in a mammal.

29. The use according to claim 28, wherein the immune response is an anti-cancer immune response.

30. A conjugate comprising a (1) PD-L1 binding agent of any one of claims 1-14 and a (2) payload for use as a medicament for the delivery of a payload to a cell expressing PD-L1.

31. A hybridoma or cell line that expresses a PD-L1 binding agent of any of claims 1-14.